Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 5
Submit an article Journal homepage
261
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Outcomes of second-line treatment in chronic lymphocytic leukemia – a population-based study from a well defined geographical region between 2003 and 2013

Anna AsklidDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Oncology, Karolinska University Hospital, Stockholm, Sweden;
,
Maria WinqvistDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden;
,
Sandra Eketorp SylvanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden;
,
Agnes MattssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Internal Medicine, Södersjukhuset, Stockholm, Sweden;
,
Einar BjörgvinssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Oncology, Karolinska University Hospital, Stockholm, Sweden;
,
Frans SøltoftJanssen Nordic, Birkerød, Denmark;
,
Johanna RepitsPreviously at Janssen Nordic, Stockholm, Sweden;
,
Joris DielsJanssen EMEA, Antwerp, Belgium
,
Anders ÖsterborgDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden;
&
Lotta HanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ;Department of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; Correspondence[email protected]
 show all
Pages 1219-1223 | Received 10 Jun 2016, Accepted 03 Oct 2016, Published online: 28 Nov 2016

References

  • Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007;48:1931–1939.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Eketorp Sylvan S, Hansson L, Karlsson C, et al. Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leuk Lymphoma. 2014;55:1774–1780.
  • Eketorp Sylvan S, Lundin J, Ipek M, et al. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) - a single region experience on consecutive patients. Ann Hematol. 2014;93:1725–1733.
  • Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–1765.
  • Cramer P, Isfort S, Bahlo J, et al. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica. 2015;100:1451–1459.
  • Klepfish A, Rachmilewitz EA, Sarid M, et al. Evaluating the impact of age and disease on survival of chronic lymphocytic leukaemia patients by a new method. Int J Clin Pract. 2009;63:1601–1603.
  • da Cunha-Bang C, Simonsen J, Rostgaard K, et al. Improved survival for patients with CLL in the era of combination chemoimmunotherapy – a Danish population based study. In: ASH, 57th Annual Meeting; 2015. Abstract 1740.
  • Kristinsson SY, Dickman PW, Wilson WH, et al. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica. 2009;94:1259–1265.
  • Pulte D, Castro FA, Jansen L, et al. Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. J Hematol Oncol. 2016;9:28.
  • Wu SJ, Chiang CJ, Lin CT, et al. Improving but inferior survival in patients with chronic lymphocytic leukemia in Taiwan: a population-based study, 1990–2004. PLoS One. 2013;8:e62930.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
  • Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. Haematologica. 2016. [Epub ahead of print]. doi: 10.3324/haematol.2016.144576.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.